$0.12
25.00% day before yesterday
Nasdaq, Jun 27, 03:30 pm CET
ISIN
US24984K1051
Symbol
DMTK

DermTech Inc Share price

$0.12
-0.27 69.23% 1M
-1.76 93.62% 6M
-1.63 93.14% YTD
-2.07 94.52% 1Y
-46.98 99.75% 3Y
-20.48 99.42% 5Y
-19.28 99.38% 10Y
Nasdaq, Closing price Thu, Jun 27 2024
ISIN
US24984K1051
Symbol
DMTK
Sector

Key figures

Market capitalization $3.29m
P/E ratio expected negative
P/S ratio expected 0.20
EV/Sales expected 1.11
Short interest 8.81%

Is DermTech Inc a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.

Financial data from DermTech Inc

Profit and loss account P&L | Balance sheet | Cash flow


TTM Annually
 
+/-
%
- -
-
- Direct costs - -
-
-
- -
-
-
- Selling and administrative expenses - -
-
-
- Research and development costs - -
-
-
- -
-
-
- Depreciation and amortization - -
-
-
EBIT (operating result) EBIT - -
-
-
Net profit - -
-
-

Figures in millions USD.

Don't miss a thing! We will send you all news about the DermTech Inc share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

DermTech Inc Share News

Negative
InvestorPlace
5 days ago
DermTech (NASDAQ: DMTK ) stock is falling on Monday as investors prepare for the molecular diagnostic company's shares to be delisted later this week. DermTech received a notice from the Listing Qualifications Department of the Nasdaq Exchange notifying it of its delisting.
Neutral
Business Wire
11 days ago
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware. The chapter 11 filing is a continuation of the Company's strategic alternatives review process. Currently, the Company ...
Neutral
Business Wire
about 2 months ago
SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its first-quarter 2024 financial results. First-Quarter 2024 Financial Results Billable sample volume declined 14 percent from the first quarter of 2023 to approximately 15,360. Test revenue was $3.7 million, up...
More DermTech Inc News

Company profile

DermTech, Inc. is a genomics company in dermatology, which engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate the early detection of skin cancers, assesses inflammatory diseases, and customizes drug treatments. Its products include adhesive skin collection kit, pigmented lesion assay, nevome, and carcinome. The company was founded in 1995 and is headquartered in La Jolla, CA.

Head office United States
CEO Bret Christensen
Founded 1995
Website www.dermtech.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now